Symbiotec Pharmalab IPO: Pharma Company’s Issue Booked 70%, GMP Hints At Strong Debut - Should You Apply

The initial public offering (IPO) of pharmaceutical and biotechnology company Symbiotec Pharmalab opened for subscription on August 24. The issue is a combination of a fresh issue and an offer for sale. The bidding window is scheduled to close on August 27.

The public issue is witnessing muted demand on the first day of subscription. Here is a detailed look at the key details of the public issue and the company's business that investors should know, according to the Red Herring Prospectus (RHP):

Symbiotec Pharmalab IPO: Offer Size And Selling Shareholders

Symbiotec Pharmalab's initial public offering comprises a fresh issue of 1.5 million shares aggregating up to Rs 150 crore, along with an offer for sale of 16.3 million shares amounting to Rs 1,607 crore. Cumulatively, the company is set to raise Rs 1,757.00 crore from its IPO. The promoters of the company include Anil Satwani, Kashish Satwani, and Sushil Satwani. Promoter holding prior to the issue was 34.47 per cent.

Symbiotec Pharmalab IPO: Price Band And Lot Size

Symbiotec Pharmalab has set the price band for its public issue at Rs 938 to Rs 988 per share. Retail investors can apply by placing bids for a minimum of 15 shares, which amounts to a minimum investment of Rs 14,820.

Small non-institutional investors (sHNI) can bid for the issue by applying for a minimum of 14 lots or 210 shares, aggregating to Rs 2,07,480. Big non-institutional investors (bHNI) must bid for a minimum of 68 lots or 1,020 shares, amounting to Rs 10,07,760.

Symbiotec Pharmalab IPO: Subscription Details

Symbiotec Pharmalab IPO has been subscribed to 70 per cent across categories as investors applied for 9.20 million shares compared to the 13.12 million shares set aside for the category. Qualified institutional buyers (QIBs) booked their quota of 35 per cent as they applied for 1.32 million shares compared to the 3.73 million shares offered for subscription.

Non-institutional investors (NIIs) subscribed to their quota 87 per cent as they placed bids for 2.44 million shares compared to the 2.80 million shares offered for subscription. Retail Individual Investors(RIIs) booked their quota at 83 per cent as they applied for 5.4 million shares compared to the 6.54 million shares set aside for the category. Employees of the company subscribed to their quota 1.19 times as they applied for 42,075 shares compared to the 35,377 shares set aside for the category.

Symbiotec Pharmalab IPO: GMP

The current trends in the Grey Market Premium (GMP) for Symbiotec Pharmalab shares indicate a premium of Rs 395 above the upper end of the price band. Since the upper end of the price band is Rs 988, the estimated listing price for the stock is Rs 1383, indicating an expected listing gain of 39.98 per cent per share.

Symbiotec Pharmalab IPO: Key Financials

In the fiscal year ended March 31, 2026, Symbiotec Pharmalab's total income stood at Rs 872.26 crore, increasing by 15.38 per cent from Rs 755.98 crore in the preceding fiscal. The company posted a profit after tax of Rs 109.90 crore in the same period, indicating an increase of 13.54 per cent compared to the profit after tax of Rs 96.79 crore in the preceding fiscal.

Symbiotec Pharmalab: Business Model

Symbiotec Pharmalab is a pharmaceutical and biotechnology company. The company operates three verticals: organic chemistry, biotechnology, and complex injectables. The company uses its capabilities to operate as a contract development and manufacturing organisation (CDMO) for speciality pharmaceutical and nutraceutical companies globally. The company derives almost all of its revenue from manufacturing and selling APIs to the pharmaceutical industry. It holds global leadership in specific niche segments, particularly corticosteroid and steroidal hormone APIs. This revenue is highly concentrated among its key products, with its top five APIs accounting for 62.27 per cent of its revenue from operations in Fiscal 2026.

Symbiotec Pharmalab: Competitors

The company operates in a highly competitive market within its API manufacturing business and in its role as a CDMO. Listed peers in the domestic market include Laurus Labs, Cohance Lifesciences, Divi's Laboratories, and Concord Biotech.

Symbiotec Pharmalab IPO: Should You Apply?

Investors should assess the risks and strengths related to the company's business model before applying for the public issue in the three-day bidding window:

Symbiotec Pharmalab IPO: Key Risks

• The company derives almost all of its revenue from the sale of APIs, with its top five APIs constituting 62.27 per cent of its revenue from operations in Fiscal 2026.

• A substantial portion of revenue from operations is generated from exports to external customers outside India, exposing the company to risks associated with export sales and foreign countries.

• The company depends on certain key customers, with revenue generated from its top ten customers accounting for 57.59 per cent of its revenue from the sale of products in Fiscal 2026.

Symbiotec Pharmalab IPO: Key Strengths

• The company holds global leadership in corticosteroid and steroidal hormone APIs.

• The business maintains long-standing relationships with domestic and international customers.

• The company operates a fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.

Symbiotec Pharmalab IPO: Objective

The company intends to use the net proceeds from the fresh issue for prepayment or repayment, in full or in part, of certain outstanding borrowings availed by the company, aggregating to Rs 112.50 crore. The remaining funds will be used for general corporate purposes.